Renal Cancer

Renal cancers are key contributors of cancer related death and morbidity. Early detection and optimal primary treatment improves cure rates and reduces progression to metastasis.
Our Clinicians and scientists have developed closely integrated multi-disciplinary research teams including; exploring new markers and imaging for early detection, better modelling of early disease biology, improved methods of risk stratification and novel therapeutic window studies alongside standard clinical treatments.


Data integration techniques are brought together in the prospective clinical trial WIRE (CI: Professor Grant Stewart).

Further information on the CRUK Cambridge Centre Urological Malignancies Programme.

Data integration in renal cancer within MFICM research focuses on:


Connect with us

The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.

Find out more